CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 487 enrolled
Drug / intervention
Delgocitinib cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04871711
NCT04871711Phase 3Completed
CompareCT.gov

A Phase 3 Clinical Trial to Confirm Efficacy and Evaluate Safety of Twice-daily Delgocitinib Cream 20 mg/g Compared With Cream Vehicle for a 16-week Treatment Period in Adult Subjects With Moderate to Severe Chronic Hand Eczema (DELTA 1)

LEO Pharma·interventional·Posted May 4, 2021·Updated Apr 8, 2025

In Brief

A Phase 3 clinical trial evaluating Delgocitinib cream and Cream vehicle for Chronic Hand Eczema. Completed, enrolled 487 participants across 54 sites in 6 countries.

Detailed Summary

This was a 16-week study in adult participants with chronic hand eczema (CHE). \> The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and quality of life. \> The purpose was to assess how delgocitinib cream works to treat CHE when compared to a placebo cream with no active substance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hand Eczema
CountriesCanada, France, Germany, Italy, Poland, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 4, 2021
Enrollment StartMay 10, 2021
Primary CompletionOct 31, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.2 years ago

Interventions

Delgocitinib creamdrug

Cream for topical application

Cream vehicledrug

The cream vehicle is similar to the delgocitinib cream\> except that it does not contain any active ingredient.